Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00338104 · ClinicalTrials.gov registry record · Phase 4
Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin
A Phase 4 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
NCT00338104 is a Phase 4 study that has completed, run by Northwestern University. The registered enrollment target is 75 participants.
The verdict
NCT00338104, a Phase 4 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the optimal dose of glargine insulin when converting from intravenous short-acting continuous insulin infusions in surgical and intensive care unit patients using a prospective, controlled, parallel group, randomized study design. Note: Lantus insulin is the proprietary name for glargine insulin.
Interventions
- DRUG insulin glargine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2004-07 |
| Est. Completion | 2005-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00338104
The ClinicalTrials.gov registry entry for NCT00338104 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which insulin glargine is the first listed.
NCT00338104 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00338104 about?
NCT00338104 is a clinical study titled "Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin". The primary objective of this study is to determine the optimal dose of glargine insulin when converting from intravenous short-acting continuous insulin infusions in surgical and intensive care unit patients using a prospective, controlled, parallel group, randomized study design. Note: Lantus ins...
What is the current status of trial NCT00338104?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2004-07. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00338104?
The interventions under investigation include: insulin glargine (DRUG).
Who is sponsoring clinical trial NCT00338104?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.